A Standardised, Generic, Validated Approach to Stratify the Magnitude of Clinical Benefit That can be Anticipated From Anti-cancer Therapies

The European Society for Medical Oncology Magnitude of Clinical Benefit Scale (ESMO-MCBS)

N. I. Cherny; R. Sullivan; U. Dafni; J. M. Kerst; A. Sobrero; C. Zielinski; E. G. E. de Vries; M. J. Piccart

Disclosures

Ann Oncol. 2015;26(8):1547-1573. 

In This Article

Appendix 1

ESMOmagnitude of Clinical Benefit Scale v1.0

Appendix 2

Fabrice Andre, France; Dirk Arnold, Germany; Paolo A. Ascierto, Italy; Stefan Bielack, Germany; Jean Yves Blay, France; Federico Cappuzzo, Italy; Fatima Cardoso, Portugal; Andrés Cervantes, Spain; Fortunato Ciardiello, Italy; Alan Stuart Coates, Australia; Karina Dahl Steffensen, Denmark; Theo M. De Reijke, The Netherlands; Jean Yves Douillard, France; Reinhard Dummer, Switzerland; Tim Eisen, UK; Enriqueta Felip, Spain; Constantine Gatsonis, USA; Heikki Joensuu, Finland; Ian Judson, UK; Vesa Kataja, Finland; Roberto Labianca, Italy; Jonathan A. Ledermann, UK; Sumithra J. Mandrekar, USA; Stefan Michiels, France; Mansoor Raza Mirza, Denmark; Mustafa Özgüroğlu, Turkey; Chris Parker, UK; Camillo Porta, Italy; Noemi Reguart, Spain; Daniel J. Sargent, USA; Elżbieta Senkus, Poland; Cristiana Sessa, Switzerland; Kirsten Sundby Hall, Norway; JosepTabernero, Spain; Dongsheng Tu, Canada; Johan Vansteenkiste, Belgium.

Comments

3090D553-9492-4563-8681-AD288FA52ACE

processing....